News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Additional Data From Pfizer Inc. (PFE)'s Prevnar 13(R) Clinical Trials in Adults 50 Years and Older to be Presented at the 49th Annual Meeting of the Infectious Diseases Society of America


10/21/2011 11:36:30 AM

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that additional data from several clinical studies of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), which is being held Oct. 20-23, 2011, in Boston, Mass. The data from these studies provide support for the pending regulatory applications for the use of Prevnar 13 in adults 50 years and older to help prevent pneumococcal disease.

Read at BioSpace.com

Related News

comments powered by Disqus
   
Pneumonia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES